Search research articles
Contact Us
Filters
Showing results (111-120 of 139) with videos related to
Page
of 14
Sort By:
American Journal of Cancer Research
|
October 13, 2022
Predictive value of albumin combined with neutrophil-to-lymphocyte ratio for efficacy and safety profiles in patients with pancreatic ductal adenocarcinoma receiving liposomal irinotecan plus 5-fluorouracil and leucovorin
Yen-Yang Chen, Shun-Wen Hsueh, Shih-Hung Yang, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]
|
April 2, 2024
Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer
Cheng-Yu Tang, Shih-Hung Yang, Chung-Pin Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 18, 2022
Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study
Nai-Jung Chiang, Kien Thiam Tan, Li-Yuan Bai, et al.
Cancer
|
December 8, 2021
Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients
Hyun Cheol Chung, Yoon-Koo Kang, Zhendong Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2026
EP4 Antagonist ONO-4578 Plus Nivolumab and Chemotherapy in HER2-Negative Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer
Izuma Nakayama, Min-Hee Ryu, Sung Hee Lim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 21, 2021
Clinical and Immunologic Responses to a B-Cell Epitope Vaccine in Patients with HER2/neu-Overexpressing Advanced Gastric Cancer-Results from Phase Ib Trial IMU.ACS.001
Ursula Wiedermann, Erika Garner-Spitzer, Yee Chao, et al.
Cancers
|
February 25, 2023
Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic Cancer
Yung-Yeh Su, Nai-Jung Chiang, Yi-Hsin Yang, et al.
Scientific Reports
|
December 1, 2021
Survival outcomes of management in metastatic gastric adenocarcinoma patients
Huang-Ming Hu, Hui-Jen Tsai, Hsiu-Ying Ku, et al.
Journal of Hepato-Biliary-Pancreatic Sciences
|
February 19, 2022
Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin
Tai-Jan Chiu, Shih-Hung Yang, Sz-Chi Chiu, et al.
Frontiers in Oncology
|
July 11, 2022
Dosing Pattern and Early Cumulative Dose of Liposomal Irinotecan in Metastatic Pancreatic Cancer: A Real-World Multicenter Study
Yung-Yeh Su, Nai-Jung Chiang, Chung-Pin Li, et al.
Page
of 14
Search research articles
Search
Showing results (111-120 of 139) with videos related to
Sort By:
Page
of 14
American Journal of Cancer Research
|
October 13, 2022
Predictive value of albumin combined with neutrophil-to-lymphocyte ratio for efficacy and safety profiles in patients with pancreatic ductal adenocarcinoma receiving liposomal irinotecan plus 5-fluorouracil and leucovorin
Yen-Yang Chen, Shun-Wen Hsueh, Shih-Hung Yang, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]
|
April 2, 2024
Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer
Cheng-Yu Tang, Shih-Hung Yang, Chung-Pin Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 18, 2022
Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study
Nai-Jung Chiang, Kien Thiam Tan, Li-Yuan Bai, et al.
Cancer
|
December 8, 2021
Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients
Hyun Cheol Chung, Yoon-Koo Kang, Zhendong Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2026
EP4 Antagonist ONO-4578 Plus Nivolumab and Chemotherapy in HER2-Negative Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer
Izuma Nakayama, Min-Hee Ryu, Sung Hee Lim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 21, 2021
Clinical and Immunologic Responses to a B-Cell Epitope Vaccine in Patients with HER2/neu-Overexpressing Advanced Gastric Cancer-Results from Phase Ib Trial IMU.ACS.001
Ursula Wiedermann, Erika Garner-Spitzer, Yee Chao, et al.
Cancers
|
February 25, 2023
Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic Cancer
Yung-Yeh Su, Nai-Jung Chiang, Yi-Hsin Yang, et al.
Scientific Reports
|
December 1, 2021
Survival outcomes of management in metastatic gastric adenocarcinoma patients
Huang-Ming Hu, Hui-Jen Tsai, Hsiu-Ying Ku, et al.
Journal of Hepato-Biliary-Pancreatic Sciences
|
February 19, 2022
Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin
Tai-Jan Chiu, Shih-Hung Yang, Sz-Chi Chiu, et al.
Frontiers in Oncology
|
July 11, 2022
Dosing Pattern and Early Cumulative Dose of Liposomal Irinotecan in Metastatic Pancreatic Cancer: A Real-World Multicenter Study
Yung-Yeh Su, Nai-Jung Chiang, Chung-Pin Li, et al.
Page
of 14